Small-Molecule TNF-Alpha Inhibitors Blocking Homotrimer Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TNF-α inhibitors, such as monoclonal antibodies and receptor fusion proteins, are expensive, not suitable for oral administration, and can undermine host immunity, while small-molecule inhibitors face issues with low potency and high toxicity, limiting their clinical application.
Innovation Solution
Development of novel small-molecule TNF-α inhibitors (TIM series) that specifically bind to the binding cavity of TNF-α homodimers, inhibiting homotrimer formation and blocking downstream signaling pathways, with derivatives like TIM1c exhibiting oral bioactivity and reduced cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies or receptor fusion proteins are used as TNF-α inhibitors, then inhibition efficacy is improved, but cost increases and oral administration becomes impossible
Solution Approach 1:
The patent creates small-molecule copies that mimic the binding interface of monoclonal antibodies with TNF-α. By copying the key interaction features at a molecular level, the invention achieves similar inhibition efficacy with compounds that can be synthesized chemically and administered orally, bypassing the manufacturing and administration limitations of biologic drugs.
Solution Approach 2:
The patent replaces the complex protein-based mechanical system (monoclonal antibodies requiring injection) with small-molecule chemistry that can be administered orally. The small molecules substitute for the large protein structures while maintaining the essential binding function through different molecular mechanisms.
2Ease of manufacture
If small-molecule TNF-α inhibitors are used, then cost is reduced and oral administration becomes possible, but potency decreases and toxicity increases
Solution Approach 1:
The patent applies local quality by designing small molecules that concentrate their binding activity at specific local regions of the TNF-α surface. Rather than attempting to replicate the entire antibody binding interface, the small molecules focus on key local interaction zones, achieving high potency with reduced molecular complexity and improved safety.
Solution Approach 2:
The patent optimizes multiple molecular parameters simultaneously including size, hydrophobicity, hydrogen bonding capacity, and steric configuration. By carefully adjusting these parameters, the small molecules achieve optimal balance between binding affinity (potency) and selectivity (safety), overcoming the traditional potency-toxicity trade-off.
3Reliability
If small-molecule inhibitors are developed to be more potent, then inhibition efficacy is improved, but toxicity increases
Solution Approach 1:
The patent introduces structural intermediaries and linker groups that mediate between the pharmacophore elements and the TNF-α binding interface. These intermediary structures enhance binding affinity through cooperative interactions while also providing steric buffering that reduces off-target effects and toxicity.
Solution Approach 2:
The patent designs molecules with equipotential distribution of electrostatic and hydrophobic interactions across the binding interface. This balanced distribution creates uniform binding energy that enhances potency while avoiding localized hotspots that could cause non-specific binding and toxicity.
Data Source
AI summary
A small molecule TNF-α inhibitor is disclosed. The compound has an activity of inhibiting the formation of a TNF-α homotrimer by specifically binding to the binding cavity of a TNF-α homodimer. A composition containing the compound as well as uses of the compound and the composition in preventing or treating autoimmune diseases and/or inflammatory diseases are disclosed. Extracellular inactivation of TNF-α through protein-protein interface destruction is the most innovative and effective method for alleviating chronic systemic inflammatory states, and TIM series compounds, which have better efficacy and lower toxicity than those of existing TNF inhibitors and have oral bioavailability, can be effectively used as leading anti-inflammatory molecules.